Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies. The partnership, announced on August 26, 2026, allows SignalChem Biotech to incorporate these AI-designed technologies into custom luminescent assay development and protein-fusion services for third-party customers in research use.
This collaboration expands SignalChem's specialized contract research organization (CRO) capabilities and aligns with Sino Biological's broader strategy of integrating AI-enabled technologies across its global life science tools and services portfolio. By leveraging Monod Bio's innovations, researchers can access high-quality discovery candidates more rapidly, addressing complex biological questions and advancing research programs more efficiently.
Monod Bio's LuxSit is an AI-designed luciferase engineered for robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies offer versatile tools for developing customized assays and discovery workflows, enhancing the efficiency and precision of research applications.
Dr. Rob Burgess, Chief Business Officer of Sino Biological, highlighted the significance of the agreement: "By incorporating Monod Bio's AI-designed protein technologies into SignalChem's custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently."
Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio, expressed enthusiasm about the partnership: "SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."
The agreement underscores the growing trend of incorporating AI-driven protein design into life science tools and services. For Monod Bio, this licensing deal is a key step in commercializing its platform through partnerships. For Sino Biological and SignalChem, it enhances their ability to offer cutting-edge solutions to researchers worldwide, potentially accelerating drug discovery and other life science research.
SignalChem Biotech, with facilities across Asia, North America, and Europe, provides specialized reagents and CRO services supporting drug discovery and research. Sino Biological is an international life science tools provider. The companies noted that the development of related business may be affected by market demand, but given the broad product portfolio, revenue from this agreement is not expected to have a material impact on overall financial performance.
Monod Bio uses AI-powered de novo protein design to create novel binders, biosensors, and other functional proteins for research and diagnostic applications. Through its Monod Inside model, Monod Bio partners with life science companies to integrate its technologies into next-generation products and services. This licensing agreement is a prime example of that model in action, extending the reach of AI-designed proteins into commercial CRO offerings.
For more information about Sino Biological and SignalChem Biotech, visit www.sinobiological.com. For more about Monod Bio, visit monod.bio.
